CA2579207C - Morpholine compound - Google Patents
Morpholine compound Download PDFInfo
- Publication number
- CA2579207C CA2579207C CA2579207A CA2579207A CA2579207C CA 2579207 C CA2579207 C CA 2579207C CA 2579207 A CA2579207 A CA 2579207A CA 2579207 A CA2579207 A CA 2579207A CA 2579207 C CA2579207 C CA 2579207C
- Authority
- CA
- Canada
- Prior art keywords
- substituent
- optionally
- methyl
- morpholin
- acetamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 C=C1OC1NCC(C1)OCCN1C=* Chemical compound C=C1OC1NCC(C1)OCCN1C=* 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004261655 | 2004-09-08 | ||
| JP2004-261655 | 2004-09-08 | ||
| PCT/JP2005/017002 WO2006028284A1 (ja) | 2004-09-08 | 2005-09-08 | モルホリン化合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2579207A1 CA2579207A1 (en) | 2006-03-16 |
| CA2579207C true CA2579207C (en) | 2011-10-18 |
Family
ID=36036551
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2579207A Expired - Fee Related CA2579207C (en) | 2004-09-08 | 2005-09-08 | Morpholine compound |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US7935700B2 (https=) |
| EP (1) | EP1801108B9 (https=) |
| JP (1) | JP4970946B2 (https=) |
| KR (1) | KR101011848B1 (https=) |
| CN (1) | CN101014580B (https=) |
| CA (1) | CA2579207C (https=) |
| DK (1) | DK1801108T3 (https=) |
| ES (1) | ES2396419T3 (https=) |
| IN (1) | IN2014CN03493A (https=) |
| PL (1) | PL1801108T3 (https=) |
| PT (1) | PT1801108E (https=) |
| TW (1) | TW200619212A (https=) |
| WO (1) | WO2006028284A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1846401B1 (en) * | 2005-02-04 | 2008-06-18 | CTG Pharma S.r.l. | New 4-aminoquinoline derivatives as antimalarials |
| PL1879573T3 (pl) | 2005-05-10 | 2013-05-31 | Incyte Holdings Corp | Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania |
| US8450351B2 (en) * | 2005-12-20 | 2013-05-28 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| US8030303B2 (en) | 2006-07-11 | 2011-10-04 | Mitsubishi Tanabe Pharma Corporation | Salt of morpholine compound |
| US20080146624A1 (en) * | 2006-09-19 | 2008-06-19 | Incyte Corporation | Amidines as modulators of indoleamine 2,3-dioxygenase |
| WO2008036642A2 (en) * | 2006-09-19 | 2008-03-27 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| CL2007002650A1 (es) | 2006-09-19 | 2008-02-08 | Incyte Corp | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
| WO2008058178A1 (en) * | 2006-11-08 | 2008-05-15 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| EP2143714B1 (en) | 2007-04-04 | 2013-06-05 | Kowa Company, Ltd. | Tetrahydroisoquinoline compound |
| JP5465720B2 (ja) | 2008-07-08 | 2014-04-09 | インサイト・コーポレイション | インドールアミン２，３−ジオキシゲナーゼの阻害剤としての１，２，５−オキサジアゾール |
| JP6382816B2 (ja) * | 2013-07-24 | 2018-08-29 | 田辺三菱製薬株式会社 | 眼科疾患治療剤 |
| ES2799582T3 (es) | 2013-11-08 | 2020-12-18 | Incyte Holdings Corp | Proceso para la síntesis de un inhibidor de indoleamina 2,3-dioxigenasa |
| WO2020203822A1 (ja) * | 2019-03-29 | 2020-10-08 | 千寿製薬株式会社 | 血管新生を伴う網膜疾患の治療又は予防のための併用医薬 |
| EP4021898B1 (en) * | 2019-08-26 | 2024-05-29 | Stichting Amsterdam UMC | Inhibition of mycobacterial type vii secretion |
| MX2022007376A (es) * | 2019-12-20 | 2022-09-02 | Tenaya Therapeutics Inc | Fluoroalqull-oxadiazoles y sus usos. |
| US20230312697A1 (en) | 2020-06-11 | 2023-10-05 | Alkahest Inc. | Methods of improving retina-associated disease outcome using ccr3-inhibitors |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ284687B6 (cs) * | 1986-04-30 | 1999-02-17 | Dainippon Pharmaceutical Co., Ltd. | Substituovaný benzamidový derivát, způsob jeho výroby a farmaceutický prostředek na jeho bázi |
| JPS63264467A (ja) * | 1986-04-30 | 1988-11-01 | Dainippon Pharmaceut Co Ltd | ベンズアミド誘導体 |
| JPH03148276A (ja) * | 1989-11-01 | 1991-06-25 | Yoshitomi Pharmaceut Ind Ltd | 光学活性なピリドンカルボン酸化合物 |
| WO1997024325A1 (en) | 1995-12-28 | 1997-07-10 | Takeda Chemical Industries, Ltd. | DIPHENYLMETHANE DERIVATIVES AS MIP-1α/RANTES RECEPTOR ANTAGONISTS |
| AU729415B2 (en) | 1996-07-12 | 2001-02-01 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
| EP0916668A4 (en) | 1996-07-29 | 2000-08-16 | Banyu Pharma Co Ltd | CHEMOKIN RECEPTOR ANTAGONISTS |
| AU5522498A (en) | 1996-12-13 | 1998-07-03 | Merck & Co., Inc. | Substituted aryl piperazines as modulators of chemokine receptor activity |
| CA2329777A1 (en) | 1998-04-27 | 1999-11-04 | Dashyant Dhanak | Ccr-3 receptor antagonists |
| JP2002512960A (ja) | 1998-04-27 | 2002-05-08 | スミスクライン・ビーチャム・コーポレイション | Ｃｃｒ−３受容体アンタゴニスト |
| JP3421323B2 (ja) | 1998-11-20 | 2003-06-30 | エフ．ホフマン−ラ ロシュ アーゲー | ピペリジンｃｃｒ−３受容体拮抗薬 |
| CN1149214C (zh) | 1998-12-04 | 2004-05-12 | 东丽株式会社 | 三唑并衍生物和含有它们作为有效组分的趋化因子抑制剂 |
| WO2000053600A1 (en) * | 1999-03-11 | 2000-09-14 | Banyu Pharmaceutical Co., Ltd. | Novel piperidine derivatives |
| BR0009338A (pt) | 1999-03-26 | 2001-12-26 | Astrazeneca Ab | Composto, processo para a preparação do mesmo,composição farmacêutica, processo para apreparação da mesma, uso de um composto, e,método de tratamento de uma doençainflamatória em um paciente sofrendo ou em riscode dita doença |
| SE9902987D0 (sv) | 1999-08-24 | 1999-08-24 | Astra Pharma Prod | Novel compounds |
| AU2001280187A1 (en) | 2000-08-28 | 2002-03-13 | Toray Industries, Inc. | Cyclic amine derivatives |
| BR0114321A (pt) | 2000-09-29 | 2003-07-01 | Glaxo Group Ltd | Composto, composição farmacêutica, uso de um composto, método de tratamento ou profilaxia de doenças inflamatórias, e, processo para preparar um composto |
| EP1324990B1 (en) * | 2000-09-29 | 2014-10-29 | Glaxo Group Limited | Morpholin-acetamide derivatives for the treatment of inflammatory diseases |
| GB0104050D0 (en) | 2001-02-19 | 2001-04-04 | Astrazeneca Ab | Chemical compounds |
| EP1389616B1 (en) | 2001-04-27 | 2011-07-27 | Mitsubishi Tanabe Pharma Corporation | 3,4-Dihalobenzylpiperidine derivatives and their medical use |
| GB0207436D0 (en) | 2002-03-28 | 2002-05-08 | Glaxo Group Ltd | Novel compounds |
| GB0208158D0 (en) | 2002-03-28 | 2002-05-22 | Glaxo Group Ltd | Novel compounds |
| GB0207439D0 (en) | 2002-03-28 | 2002-05-08 | Glaxo Group Ltd | Novel compounds |
| TW200400035A (en) | 2002-03-28 | 2004-01-01 | Glaxo Group Ltd | Novel compounds |
| GB0207445D0 (en) | 2002-03-28 | 2002-05-08 | Glaxo Group Ltd | Novel compounds |
| GB0207443D0 (en) * | 2002-03-28 | 2002-05-08 | Glaxo Group Ltd | Novel compounds |
| GB0212357D0 (en) | 2002-05-29 | 2002-07-10 | Glaxo Group Ltd | Novel compounds |
| GB0212355D0 (en) | 2002-05-29 | 2002-07-10 | Glaxo Group Ltd | Novel compounds |
| CN1665506A (zh) * | 2002-07-02 | 2005-09-07 | 霍夫曼-拉罗奇有限公司 | 作为ccr－3受体拮抗剂ⅸ的2,5－取代的嘧啶衍生物 |
-
2005
- 2005-09-08 IN IN3493CHN2014 patent/IN2014CN03493A/en unknown
- 2005-09-08 DK DK05783689.2T patent/DK1801108T3/da active
- 2005-09-08 KR KR1020077007863A patent/KR101011848B1/ko not_active Expired - Fee Related
- 2005-09-08 PL PL05783689T patent/PL1801108T3/pl unknown
- 2005-09-08 PT PT57836892T patent/PT1801108E/pt unknown
- 2005-09-08 WO PCT/JP2005/017002 patent/WO2006028284A1/ja not_active Ceased
- 2005-09-08 ES ES05783689T patent/ES2396419T3/es not_active Expired - Lifetime
- 2005-09-08 JP JP2006535186A patent/JP4970946B2/ja not_active Expired - Fee Related
- 2005-09-08 CA CA2579207A patent/CA2579207C/en not_active Expired - Fee Related
- 2005-09-08 EP EP05783689.2A patent/EP1801108B9/en not_active Expired - Lifetime
- 2005-09-08 CN CN2005800301370A patent/CN101014580B/zh not_active Expired - Fee Related
- 2005-09-08 TW TW094130939A patent/TW200619212A/zh not_active IP Right Cessation
- 2005-09-08 US US11/662,228 patent/US7935700B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| PT1801108E (pt) | 2012-12-03 |
| TWI367209B (https=) | 2012-07-01 |
| PL1801108T3 (pl) | 2013-04-30 |
| EP1801108A4 (en) | 2010-10-13 |
| US20070265257A1 (en) | 2007-11-15 |
| JPWO2006028284A1 (ja) | 2008-05-08 |
| KR20070099528A (ko) | 2007-10-09 |
| ES2396419T3 (es) | 2013-02-21 |
| CN101014580A (zh) | 2007-08-08 |
| CN101014580B (zh) | 2011-05-04 |
| DK1801108T3 (da) | 2013-02-18 |
| TW200619212A (en) | 2006-06-16 |
| EP1801108B1 (en) | 2012-11-14 |
| WO2006028284A1 (ja) | 2006-03-16 |
| JP4970946B2 (ja) | 2012-07-11 |
| US7935700B2 (en) | 2011-05-03 |
| CA2579207A1 (en) | 2006-03-16 |
| KR101011848B1 (ko) | 2011-02-01 |
| EP1801108B9 (en) | 2013-11-20 |
| IN2014CN03493A (https=) | 2015-07-03 |
| EP1801108A1 (en) | 2007-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2579207C (en) | Morpholine compound | |
| CN108290879B (zh) | 用作irak抑制剂的杂芳基化合物及其用途 | |
| JP4261914B2 (ja) | 新規ベンジルピペリジン化合物 | |
| US20030069169A1 (en) | Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-AMP associated disorders | |
| CN112996529B (zh) | Matriptase 2抑制剂及其用途 | |
| US20080280925A1 (en) | Amines as Small Molecule Inhibitors | |
| CA3075751A1 (en) | Pyrazolopyrimidinone compounds and uses thereof | |
| JP2021522253A (ja) | 化合物及びその使用 | |
| CA2694284A1 (en) | Heterocyclic compounds useful as raf kinase inhibitors | |
| CA2693182A1 (en) | Pyrimidine compounds, methods of synthesis thereof, and use thereof in the treatment of raf kinase-mediated disorders | |
| EP1363898A1 (en) | Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same | |
| NZ551508A (en) | Adamantyl-acetamide derivatives as inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme | |
| JP6581745B2 (ja) | 抗ｂ型肝炎ウイルスのピラゾール−オキサゾリジノン系化合物 | |
| WO2008057775A2 (en) | Heterocyclic amide compounds useful as kinase inhibitors | |
| WO2004022554A1 (en) | Quinazolinone derivatives | |
| AU2016338992B2 (en) | Dopamine D3 receptor antagonists having a morpholine moiety | |
| WO2023227734A1 (en) | Flavivirus inhibitors | |
| ES2366114T3 (es) | Derivados de 3,4-dihalobencilpiperidina y su uso médico. | |
| AU2002245601A1 (en) | Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-AMP associated disorders | |
| AU2002254095A1 (en) | Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20210908 |